Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation PK study of herombopag in children with aplastic anemia
ChiCTR2300068312Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hetrombopag in aplastic anemia (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Herombopag pharmacokinetic indices, Incidence of adverse events during herombopag treatment and 1 more. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2300068312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068312.